首頁 > 市場調查報告書 > 醫療設備

體外診斷癌症癌症診斷

市場調查報告書

商品編碼

1701011

下一代癌症診斷市場規模、佔有率、成長分析、按產品/服務、按技術、按癌症類型、按應用、按最終用途、按地區 - 2025 年至 2032 年行業預測

Next Generation Cancer Diagnostics Market Size, Share, and Growth Analysis, By Product and Services, By Technology, By Cancer Type, By Application, By End Use, By Region - Industry Forecast 2025-2032

出版日期: 2025年04月02日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

下一代癌症診斷市場預計將在 2023 年達到 159 億美元，從 2024 年的 188.4 億美元成長到 2032 年的 732.6 億美元，預測期內（2025-2032 年）的複合年成長率為 18.5%。

隨著先進診斷儀器、套件和試劑的商業化，市場正從傳統的實驗室檢測轉變為快速就地檢驗。這種演變，特別是伴隨診斷的興起為個人化基因組醫學提供了寶貴的機會，大大推動了市場的成長。近年來，全球範圍內報告的非何傑金氏淋巴瘤和其他常見癌症病例超過 544,000 例，這說明全球癌症發生率不斷上升，這凸顯了對這些創新診斷工具的需求。癌症是全球第二大死因，每年造成超過 960 萬人死亡。因此，下一代診斷技術的開發正在提高準確性和可負擔性，促進更早的檢測並在充滿挑戰的全球醫療保健領域改善患者的治療效果。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業市場定位（2024年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2024年）
主要企業簡介
- 公司詳情
- 產品系列分析
- 公司分部佔有率分析
- 收益與前一年同期比較對比（2022-2024 年）
  主要企業簡介
  - 羅氏控股公司（瑞士）
  - 賽默飛世爾科技公司（美國）
  - Illumina公司（美國）
  - 雅培實驗室（美國）
  - QIAGEN NV（Germany/Netherlands）
  - 安捷倫科技公司（美國）
  - Bio-Rad Laboratories, Inc.（美國）
  - 碧迪公司（BD）（美國）
  - Myriad Genetics, Inc.（美國）
  - Guardant Health, Inc.（美國）
  - 精確科學公司（美國）
  - 丹納赫公司（美國）
  - 西門子醫療股份公司（德國）
  - Hologic公司（美國）
  - GE醫療（美國）
  - 諾華公司（瑞士）
  - 默克集團（德國）
  - Sysmex株式會社（日本）
  - Invitae公司（美國）

結論和建議

簡介目錄

Product Code: SQMIG35A2226

Next Generation Cancer Diagnostics Market size was valued at USD 15.9 billion in 2023 and is poised to grow from USD 18.84 billion in 2024 to USD 73.26 billion by 2032, growing at a CAGR of 18.5% during the forecast period (2025-2032).

The market is transitioning from traditional laboratory testing to rapid point-of-care testing, driven by the commercialization of advanced diagnostic devices, kits, and reagents. This evolution is significantly boosting market growth, particularly with the rise of companion diagnostics, which present valuable opportunities in personalized genomic medicine. The increasing global cancer prevalence underscores the demand for these innovative diagnostic tools, as evidenced by over 544,000 cases of non-Hodgkin lymphoma and other high-profile cancers reported in recent years. With cancer as the second-leading cause of mortality worldwide, highlighting more than 9.6 million deaths annually, the need for advanced cancer detection is critical. Consequently, the development of next-generation diagnostics is enhancing accuracy and affordability, promoting early detection and improved patient outcomes amid a global healthcare landscape facing severe challenges.

Top-down and bottom-up approaches were used to estimate and validate the size of the Next Generation Cancer Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Next Generation Cancer Diagnostics Market Segments Analysis

Global Next Generation Cancer Diagnostics Market is segmented by Product and Services, Technology, Cancer Type, Application, End Use and region. Based on Product and Services, the market is segmented into Products and Services. Based on Technology, the market is segmented into Next-generation sequencing (NGS), Polymerase chain reaction (PCR), DNA microarrays, Multiplexing and Other technologies. Based on Cancer Type, the market is segmented into Breast cancer, Lung cancer, Colorectal cancer, Prostate cancer, Cervical cancer, Liver cancer and Other cancer types. Based on Application, the market is segmented into Screening and early detection, Prognostics and monitoring, Therapy selection, Recurrence monitoring and Other applications. Based on End Use, the market is segmented into Hospitals & clinics, Diagnostic laboratories, Academic & research institutions and Other end users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Next Generation Cancer Diagnostics Market

The increasing demand for personalized medicine significantly contributes to the expansion of the next generation cancer diagnostics market. Personalized medicine focuses on customizing treatments according to each patient's unique genetic makeup and specific characteristics, ensuring a more effective approach to cancer care. Advanced diagnostics tools are essential in this context, as they can pinpoint patients who are most likely to respond positively to tailored therapies. By facilitating the identification of suitable candidates for these individualized treatments, next generation cancer diagnostics not only enhance treatment efficacy but also drive innovation and growth within the healthcare sector.

Restraints in the Next Generation Cancer Diagnostics Market

The Next Generation Cancer Diagnostics market faces significant challenges stemming from unclear reimbursement policies and the slow evolution of these frameworks. This ambiguity hinders the widespread adoption of innovative technologies, complicating the decision-making process for healthcare providers and patients regarding the justification of expenses linked to such diagnostic tests. Furthermore, reimbursement policies differ greatly across various countries, regions, and healthcare systems, leading to a fragmented landscape. In many instances, these policies are still under development, reflecting an absence of consensus on the appropriate reimbursement strategies for these advanced diagnostic solutions, which ultimately restricts their integration into clinical practice.

Market Trends of the Next Generation Cancer Diagnostics Market

The Next Generation Cancer Diagnostics market is increasingly shifting towards liquid biopsy tests, reflecting a significant trend in oncology diagnostics. These minimally invasive tests, which utilize blood, urine, and other bodily fluids to identify cancerous cells and biomarkers, are gaining traction due to their cost-effectiveness and ability to deliver rapid, reliable results. As healthcare providers seek more efficient diagnostic tools, the adoption of liquid biopsies is expected to grow, prompting substantial investments from biotech firms and research institutions. This evolving landscape is anticipated to reshape cancer detection and monitoring, driving innovation and improving patient outcomes in oncology.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Next Generation Cancer Diagnostics Market Size by Product and Services & CAGR (2025-2032)

Market Overview
Products
- Instruments
- Kits & consumables
Services

Global Next Generation Cancer Diagnostics Market Size by Technology & CAGR (2025-2032)

Market Overview
Next-generation sequencing (NGS)
Polymerase chain reaction (PCR)
DNA microarrays
Multiplexing
Other technologies

Global Next Generation Cancer Diagnostics Market Size by Cancer Type & CAGR (2025-2032)

Market Overview
Breast cancer
Lung cancer
Colorectal cancer
Prostate cancer
Cervical cancer
Liver cancer
Other cancer types

Global Next Generation Cancer Diagnostics Market Size by Application & CAGR (2025-2032)

Market Overview
Screening and early detection
Prognostics and monitoring
Therapy selection
Recurrence monitoring
Other applications

Global Next Generation Cancer Diagnostics Market Size by End Use & CAGR (2025-2032)

Market Overview
Hospitals & clinics
Diagnostic laboratories
Academic & research institutions
Other end users

Global Next Generation Cancer Diagnostics Market Size & CAGR (2025-2032)

North America (Product and Services, Technology, Cancer Type, Application, End Use)
- US
- Canada
Europe (Product and Services, Technology, Cancer Type, Application, End Use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product and Services, Technology, Cancer Type, Application, End Use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product and Services, Technology, Cancer Type, Application, End Use)
- Brazil
- Rest of Latin America
Middle East & Africa (Product and Services, Technology, Cancer Type, Application, End Use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN N.V. (Germany/Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (BD) (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exact Sciences Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hologic, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GE Healthcare (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Invitae Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments